Get the Stockscreener App
10.26
1.18%
0.12
After Hours:
10.31
0.05
+0.49%
Moonlake Immunotherapeutics stock is traded at $10.26, with a volume of 1.07M.
It is up +1.18% in the last 24 hours and down -15.90% over the past month.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
See More
Previous Close:
$10.14
Open:
$10.16
24h Volume:
1.07M
Relative Volume:
0.52
Market Cap:
$873.19M
Revenue:
Net Income/Loss:
$-230.32M
P/E Ratio:
-2.9099
EPS:
-3.5259
Net Cash Flow:
$-196.04M
1W Performance:
-3.02%
1M Performance:
-15.90%
6M Performance:
-43.06%
1Y Performance:
+3.74%
1-Day Range:
$10.14
$10.51
1-Week Range:
$10.01
$11.09
52-Week Range:
$8.80
$23.29
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Name
Moonlake Immunotherapeutics
Sector
Industry
Phone
41 41 510 8022
Address
DORFSTRASSE 29, ZUG
Compare MLTX vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
10.26 | 873.19M | 0 | -230.32M | -196.04M | -3.5259 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-23-26 | Upgrade | Wolfe Research | Underperform → Outperform |
| Mar-19-26 | Upgrade | Rothschild & Co Redburn | Neutral → Buy |
| Jan-15-26 | Downgrade | Goldman | Neutral → Sell |
| Jan-09-26 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-03-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-02-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-01-25 | Downgrade | Goldman | Buy → Neutral |
| Sep-30-25 | Downgrade | Citigroup | Buy → Neutral |
| Sep-30-25 | Downgrade | Wolfe Research | Outperform → Underperform |
| Sep-29-25 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-29-25 | Downgrade | Jefferies | Buy → Hold |
| Sep-29-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-29-25 | Downgrade | Stifel | Buy → Hold |
| Jul-28-25 | Initiated | Rothschild & Co Redburn | Neutral |
| May-19-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-18-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-17-25 | Upgrade | Goldman | Neutral → Buy |
| Nov-05-24 | Resumed | Wedbush | Outperform |
| Aug-26-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Nov-02-23 | Initiated | Stifel | Buy |
| Sep-14-23 | Downgrade | Bryan Garnier | Buy → Neutral |
| Aug-31-23 | Initiated | Needham | Buy |
| Jun-15-23 | Initiated | Barclays | Equal Weight |
| May-01-23 | Initiated | Guggenheim | Buy |
| Mar-22-23 | Initiated | Wedbush | Outperform |
| Mar-09-23 | Initiated | BTIG Research | Buy |
| Feb-14-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-02-23 | Initiated | Bryan Garnier | Buy |
| Nov-11-22 | Initiated | Jefferies | Buy |
| Aug-25-22 | Initiated | SVB Leerink | Outperform |
| Jul-21-22 | Initiated | H.C. Wainwright | Buy |
| Jul-07-22 | Initiated | Cowen | Outperform |
View All
Moonlake Immunotherapeutics Stock (MLTX) Latest News
Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight - GlobeNewswire Inc.
(MLTX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near - Yahoo Finance
MoonLake Immunotherapeutics advances sonelokima... - Pluang
MoonLake Immunotherapeutics: The Bull Case Does Not Require Clinical Supremacy - Seeking Alpha
GOOG: Alphabet IncOrdinary SharesClass C Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
(MLTX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Deep Track Capital, LP Expands MoonLake Immunotherapeutics (MLTX) Stake With 1.59 Million Share Purchase - GuruFocus
MoonLake (MLTX) Quarterly Figures: Profit Per Share Falls Below Its Benchmark in the Available Record; Closing Move - Vinanet
Lost Money on MoonLake Immunotherapeutics (MLTX)? Urged to Join C - The National Law Review
Lost Money on MoonLake Immunotherapeutics (MLTX)? Urged to Join C - The National Law Review
MoonLake (MLTX) Financial Results: EPS Does Not Reach the Reported Estimate; After Results: Shares Finish 5.97% Lower on the DayEarnings Recovery Stocks - vinanet.vn
Class Action Alert: Levi & Korsinsky Reminds MoonLake (MLTX) Investors of December 15, 2025 Deadline - The National Law Review
MLTX Stock Heads Into Investor Day With FDA Momentum – What Traders Should Watch Next Week - Stocktwits
Dimensional Fund Advisors LP Has $490,000 Position in MoonLake Immunotherapeutics $MLTX - marketbeat.com
Cormorant Asset Management (MLTX) discloses 4.35% MoonLake Immunotherapeutics stake - stocktitan.net
T. Rowe Price (MLTX holder) discloses 5.3% MoonLake Immunotherapeutics position - Stock Titan
Deep Track reports 7.99M-share, 9.74% stake in MoonLake (MLTX) in 13G/A - Stock Titan
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Raises Target Price to $50 - Moomoo
MoonLake Immunotherapeutics (MLTX) Receives a Hold from RBC Capital - The Globe and Mail
Guggenheim Reaffirms Their Buy Rating on MoonLake Immunotherapeutics (MLTX) - The Globe and Mail
MLTX LAWSUIT ALERT: Levi & Korsinsky Notifies MoonLake Immunother - The National Law Review
MoonLake’s Psoriatic Arthritis Drug Shows Promise In Late-Stage Study - Sahm
Avoiding Lag: Real-Time Signals in (MLTX) Movement - Stock Traders Daily
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 5.3%Time to Sell? - MarketBeat
MoonLake’s Sonelokimab Meets Primary Endpoint in Phase 3 PsA Trial - The Dermatology Digest
MoonLake’s nanobody boosts PsA indication hopes after Phase III success - Yahoo
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and MoonLake Immunotherapeutics (MLTX) - The Globe and Mail
MoonLake’s nanobody boosts PsA indication hopes after Phase III success - Clinical Trials Arena
A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $30 to $34 - Moomoo
MoonLake's nanobody clears Phase III test, but shares slip - The Pharma Letter
MoonLake Immunotherapeutics (MLTX) Stock Analysis: 61% Upside Potential Amid Biotech Innovations - DirectorsTalk Interviews
Why is MoonLake Immunotherapeutics scared of releasing data on its drug candidate? - STAT
How Psoriatic Arthritis Trial Success and Q2 Losses Could Shape MoonLake Immunotherapeutics (MLTX) Investors - simplywall.st
MoonLake touts Phase III PsA data, but investors may have wanted more - FirstWord Pharma
Moonlake Immunotherapeutics Files For Mixed Shelf Offering, Size Not Disclosed - TradingView
Why is MoonLake Immunotherapeutics stock plunging today? By Investing.com - Investing.com India
MoonLake Immunotherapeutics Releases Q2 2026 Financial Results - AlphaStreet
What's Going On With MoonLake Stock Monday?MoonLake (NASDAQ:MLTX) - Benzinga
MoonLake's sonelokimab meets all endpoints in Phase 3 IZAR-1 psoriatic arthritis trial - Dealroom
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap DownHere's What Happened - MarketBeat
Moomoo AI Day 7 (Aug'26)Moonlake Immunotherapeutic (MLTX.US) R&D expenses and cash on hand - Moomoo
RevMed, BeOne make clinical trial, Asia deal; MoonLake reports Phase 3 win - Endpoints News
Traders Buy Large Volume of MoonLake Immunotherapeutics Call Options (NASDAQ:MLTX) - MarketBeat
MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial - Fierce Biotech
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial - dermatologytimes.com
MoonLake Immunotherapeutics Announces Q2 2026 Financial Results with Increased Net Loss and Cash Reserves - Kalkine Media
MoonLake Immunotherapeutics Announces Q2 2026 Financial Results and Positive Phase 3 IZAR-1 Trial Data for Sonelokimab in Psoriatic Arthritis - Kalkine Media
MoonLake’s Psoriatic Arthritis Drug Shows Promise In Phase 3 Trial – Retail Shrugs Off Premarket Slide, Says ‘Pipeline Is Intact’ - Yahoo Finance
Moonlake Immunotherapeutics Stock (MLTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Moonlake Immunotherapeutics Stock (MLTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Reich Kristian | Chief Scientific Officer |
Jul 22 '26 |
Sale |
20.00 |
2,448 |
48,960 |
2,712,298 |
| Reich Kristian | Chief Scientific Officer |
Jul 21 '26 |
Sale |
20.02 |
50,000 |
1,001,000 |
2,714,746 |
| Reich Kristian | Chief Scientific Officer |
Jul 20 '26 |
Sale |
20.09 |
43,700 |
877,933 |
2,764,746 |
| Reich Kristian | Officer |
Jul 15 '26 |
Proposed Sale |
19.44 |
150,000 |
2,916,000 |
0 |
| Reich Kristian | Chief Scientific Officer |
Jul 15 '26 |
Sale |
20.01 |
16,105 |
322,261 |
2,808,446 |
| Santos da Silva Jorge | Chief Executive Officer |
Jul 10 '26 |
Sale |
20.02 |
68,289 |
1,367,146 |
2,774,893 |
| Santos da Silva Jorge | Chief Executive Officer |
Jul 09 '26 |
Sale |
20.01 |
33,936 |
679,059 |
2,843,182 |
| Santos da Silva Jorge | Chief Executive Officer |
Jul 01 '26 |
Sale |
20.03 |
47,775 |
956,933 |
2,877,118 |
| Santos da Silva Jorge | Officer |
Jun 30 '26 |
Proposed Sale |
20.03 |
150,000 |
3,004,500 |
0 |
| Bodenstedt Matthias | Chief Financial Officer |
Jun 22 '26 |
Sale |
22.04 |
39,120 |
862,205 |
1,115,435 |
2.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):